Healthcare to All. Co. Ltd.
Emiko Yoshida. MSc.
Consultant, H2A Co. Ltd.
Emiko Yoshida
MSc. Health Economics, University of York
European Market Access University Diploma, Université Claude Bernard Lyon 1
Emiko started her career as a registered clinical nurse in both the UK and Japan, specialised in neurosurgery and intensive care management.
After gaining MSc. Health Economics, she has been involved in various local, regional and global level projects in healthcare policy, market access and health economics evidence development. Her clients include but are not limited to pharmaceutical and medical device companies, medical professional associations and government.
H2A Business partners
A successful HEOR study that is accepted by HTA organization and peer reviewed journal is developed based on professional knowledge and business experience. A successful PRMA project that makes sense in a company should be based on fruitful professional experience and up-to-date local policy changes.
H2A has official collaboration to the following agencies to deliver the best HEOR and PRMA project to meet client needs.
Lucid Health Consulting Pty. Ltd.,
a HEOR consulting firm in Australia and the US
George is an expert in global pricing and reimbursement, including HTA submission. With his academic background with Bsc (Hons), GradDipEEpi, and MAICD, he developed his expertise in HEOR and PRMA through working in global market access in Schering-Plough and global HEOR in Johnson and Johnson, he opened his business in HEOR in Australia. He has many experience in HTA submission.
George Papadopoulos
The founder and managing director, Lucid Health Consulting Pty. Ltd.
Satoru GK,
a market access consulting firm in Japan
Bruno is a former Executive Officer and Head of Market Access at Bayer Yakuhin, Ltd., and former head of the Medical Economic Evaluation Committee of EFPIA-Japan.
After graduating from ESCP, a business school in Paris, and with a MA in Japanese, over the last 30 years, Bruno worked in government and in industry, mostly in Japan and in Singapore.
Since 2016, he operates as an independent consultant, assisting pharmaceutical and devices companies on data generation, market access, patient relations and, more generally business development, across several therapeutic indications.
Bruno Rossi
Consultant, Satoru G.K.